[go: up one dir, main page]

MA39963A - Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin - Google Patents

Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin

Info

Publication number
MA39963A
MA39963A MA039963A MA39963A MA39963A MA 39963 A MA39963 A MA 39963A MA 039963 A MA039963 A MA 039963A MA 39963 A MA39963 A MA 39963A MA 39963 A MA39963 A MA 39963A
Authority
MA
Morocco
Prior art keywords
methods
ibd
smad7
subject
disclosed
Prior art date
Application number
MA039963A
Other languages
English (en)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MA39963A publication Critical patent/MA39963A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des méthodes de traitement d'un sujet atteint d'une maladie inflammatoire chronique de l'intestin (mici) faisant appel à une thérapie anti-smad7, par exemple à l'aide d'un oligonucléotide antisens smad7, de manière à réduire les niveaux de crp. L'invention concerne des méthodes de traitement et de prise en charge d'une mici chez un sujet à l'aide d'une thérapie anti-smad7, par exemple faisant appel à un oligonucléotide antisens smad7, sur la base des niveaux de crp. L'invention concerne également des procédés permettant de déterminer si un sujet atteint d'une mici répond, ou est susceptible de répondre, à un traitement consistant en une thérapie anti-smad7. La réduction des niveaux de crp peut être corrélée à une rémission de la mici ou à une baisse du score d'activité clinique. La présente invention concerne également le traitement d'une mici à l'aide d'une thérapie anti-smad7 (par exemple faisant appel à un oligonucléotide antisens) en combinaison avec un agent supplémentaire. L'invention concerne également des compositions pharmaceutiques et des nécessaires associés.
MA039963A 2014-05-09 2015-05-08 Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin MA39963A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461991326P 2014-05-09 2014-05-09
US201462065609P 2014-10-17 2014-10-17
US201462065606P 2014-10-17 2014-10-17

Publications (1)

Publication Number Publication Date
MA39963A true MA39963A (fr) 2017-03-15

Family

ID=53059121

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039963A MA39963A (fr) 2014-05-09 2015-05-08 Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin

Country Status (11)

Country Link
US (1) US10473669B2 (fr)
EP (1) EP3140658A2 (fr)
JP (1) JP2017515896A (fr)
KR (1) KR20170005058A (fr)
CN (1) CN106573065A (fr)
AU (1) AU2015257589A1 (fr)
CA (1) CA2948411A1 (fr)
MA (1) MA39963A (fr)
MX (1) MX2016014624A (fr)
RU (1) RU2016147569A (fr)
WO (1) WO2015169966A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
EP3207136A1 (fr) * 2014-10-17 2017-08-23 Nogra Pharma Limited Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
CA3014383A1 (fr) * 2016-02-24 2017-08-31 Nogra Pharma Limited Procedes de traitement de la maladie cƒliaque en inhibant smad7
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
CA3047302C (fr) * 2016-12-14 2024-01-02 Tracy WARREN Systeme et procedes de developpement et d'utilisation d'un composant d'action a base de microbiome pour la sante d'un patient
WO2019023439A1 (fr) * 2017-07-28 2019-01-31 Celgene Corporation Procédé de préparation de composés oligonucléotidiques
KR102824401B1 (ko) * 2018-11-30 2025-06-25 아레나 파마슈티칼스, 인크. S1p1 수용체와 관련된 병태의 치료 방법
WO2021034727A1 (fr) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations et production et purification d'interleukines
CN115552005A (zh) * 2020-04-24 2022-12-30 诺格拉制药有限公司 Smad7反义寡核苷酸(aso)的组合物及其使用方法
US20230287417A1 (en) * 2020-07-06 2023-09-14 Vivtex Corporation Mucopenetrating formulations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257932A1 (en) * 1997-02-28 2006-11-16 Yaron Ilan Treatment of Crohn's disease
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20050118655A1 (en) 2003-11-17 2005-06-02 University Of Iowa Research Foundation Use of parasitic biological agents for diseases prevention and control
RS56049B1 (sr) 2008-11-13 2017-09-29 Nogra Pharma Ltd Antisens kompozicije i postupci za pripremu i upotrebu istih
CA2777800C (fr) * 2009-10-15 2019-11-12 Crescendo Bioscience Biomarqueurs et procedes de mesure et de surveillance de l'activite d'une maladie inflammatoire
TR201000680A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
WO2012154987A1 (fr) * 2011-05-10 2012-11-15 Nestec Sa Méthodes de profilage de l'activité d'une maladie pour une prise en charge thérapeutique personnalisée
KR102099990B1 (ko) 2011-09-15 2020-04-13 노그라 파마 리미티드 항-smad7 요법의 반응성을 모니터링하는 방법
RU2667960C2 (ru) 2012-04-18 2018-09-25 Ногра Фарма Лимитед Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации
JP2015517521A (ja) * 2012-05-19 2015-06-22 ドクトル ファルク ファルマ ゲーエムベーハー 過敏性腸症候群の治療のための５−アミノサリチル酸を用いた組成物および方法
US9772334B2 (en) * 2012-12-10 2017-09-26 The Regents Of The University Of California Inflammatory bowel disease markers and therapies for colitis-associated intestinal fibrosis
CN105008394B (zh) 2013-03-15 2021-10-22 诺格尔制药有限公司 治疗结肠直肠癌的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2015155552A (ru) * 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2016059243A2 (fr) 2014-10-17 2016-04-21 Nogra Pharma Limmited Procédés de dosage et de suivi d'un traitement avec un oligonucléotide antisens de smad7 utilisant des teneurs en marqueurs biologiques
EP3207136A1 (fr) 2014-10-17 2017-08-23 Nogra Pharma Limited Procédés et compositions pour le traitement d'un sujet au moyen d'un oligonucléotide antisens de smad7
WO2017055611A2 (fr) 2015-09-30 2017-04-06 Nogra Pharma Limited Méthodes d'utilisation d'oligonucléotides antisens smad7 sur la base de l'expression de biomarqueurs
CA3014383A1 (fr) 2016-02-24 2017-08-31 Nogra Pharma Limited Procedes de traitement de la maladie cƒliaque en inhibant smad7
US20190328770A1 (en) 2016-12-30 2019-10-31 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis

Also Published As

Publication number Publication date
RU2016147569A (ru) 2018-06-13
WO2015169966A3 (fr) 2016-02-04
KR20170005058A (ko) 2017-01-11
MX2016014624A (es) 2017-05-25
EP3140658A2 (fr) 2017-03-15
RU2016147569A3 (fr) 2018-12-28
US20180180630A1 (en) 2018-06-28
CN106573065A (zh) 2017-04-19
JP2017515896A (ja) 2017-06-15
WO2015169966A2 (fr) 2015-11-12
AU2015257589A1 (en) 2016-11-24
CA2948411A1 (fr) 2015-11-12
US10473669B2 (en) 2019-11-12

Similar Documents

Publication Publication Date Title
MA39963A (fr) Méthodes de traitement d'une maladie inflammatoire chronique de l'intestin
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
NZ707035A (en) Gene signatures of inflammatory disorders that relate to the liver
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3693736A3 (fr) Procédés de dosage et de surveillance de traitement d'oligonucléotides antisens smad7 utilisant des niveaux de biomarqueurs
MX2017003933A (es) Metodos de tratamiento de la enfermedad hepatica.
MA39906A (fr) Polythérapies pour le traitement du cancer
WO2015172085A3 (fr) Biomarqueurs utilisables pour évaluer la réponse aux inhibiteurs de la pi3k
PH12019501010A1 (en) Arginase inhibitor combination therapies
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
PH12016502167A1 (en) Hdl theraphy markers
EP3634424A4 (fr) Compositions et procédés pour prévenir ou traiter des affections musculaires
MY182454A (en) Dihydropyrrolopyridine inhibitors of ror-gamma
MX371017B (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
EA201790802A1 (ru) Соединения против tnf
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
WO2014205266A3 (fr) Compositions et méthodes pour la détection et le traitement du glioblastome
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
MX2017015700A (es) Igfbp3 y sus usos.
EA201791933A1 (ru) Ингибирование активности olig2
MX2019000221A (es) Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma.